A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...

US health authorities are reassessing the risks of Hormone Replacement Therapy (HRT) in a meeting convened by FDA chief Marty ...

The debate over whether to use hormone therapy to treat menopausal women continues, as a Food and Drug Administration (FDA) expert panel weighs in. The panel, consisting […] ...

Dr. Marty Makary, the agency’s commissioner, said too many women avoid hormone therapy because the risks have been overstated ...

A new study suggests that hormone therapy, often used to ease symptoms of menopause like hot flashes and night sweats, may ...

The death of Shafali Jariwala has sparked a major debate on anti-ageing products, highlighting their hidden risks, lack of regulation, and the urgent need for medically guided, safer alternatives.

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

The contrast between the FDA’s clinical lens and the raw realities in the Bonafide study highlights a critical disconnect ...

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and multiple myeloma, respectively.

In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, the agency is investigating two Duchenne muscular dystrophy patient ...

FDA evaluating further regulatory actions after deaths Elevidys is the only gene therapy for Duchenne muscular dystrophy Sarepta suggested updating Elevidys' label June 24 (Reuters) - The U.S ...

The FDA has eliminated a safety monitoring requirement and eased certain restrictions that had been in place since CAR T-therapies first reached the market in 2017. The agency and financial ...